Equities Analysts Issue Forecasts for RVPH FY2024 Earnings

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Investment analysts at Zacks Small Cap increased their FY2024 earnings estimates for shares of Reviva Pharmaceuticals in a research report issued to clients and investors on Monday, December 23rd. Zacks Small Cap analyst J. Vandermosten now expects that the company will post earnings of ($0.97) per share for the year, up from their previous estimate of ($0.98). The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($1.01) per share. Zacks Small Cap also issued estimates for Reviva Pharmaceuticals’ Q4 2024 earnings at ($0.22) EPS.

Separately, EF Hutton Acquisition Co. I raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 23rd.

Reviva Pharmaceuticals Price Performance

Shares of RVPH stock opened at $1.86 on Wednesday. The firm’s 50-day moving average is $1.41 and its two-hundred day moving average is $1.25. Reviva Pharmaceuticals has a 12 month low of $0.60 and a 12 month high of $5.67. The company has a market capitalization of $62.20 million, a PE ratio of -1.68 and a beta of -0.02.

Institutional Investors Weigh In On Reviva Pharmaceuticals

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC grew its position in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 278,496 shares of the company’s stock after purchasing an additional 42,376 shares during the quarter. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent filing with the SEC. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.